The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review

References

• Obua C, Hellgren U, Ntale M, et al. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol. 2008;65(4):493–501. doi:10.1111/j.1365-2125.2007.03050.x
   PubMed Web of Science ®Google Scholar
• Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metabol Disposit. 2003;31(12):1507–1519. doi:10.1124/dmd.31.12.1507
   PubMed Web of Science ®Google Scholar
• Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008;9:403–433. doi:10.1146/annurev.genom.9.081307.164258
   PubMed Web of Science ®Google Scholar
• Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol. 2014;10(6):769–785. doi:10.1517/17425255.2014.894020
   PubMed Web of Science ®Google Scholar
• Mpye K, Matimba A, Dzobo K, Chirikure S, Wonkam A, Dandara C. Disease burden and the role of pharmacogenomics in African populations. Global Health Epidemiol Genom. 2017;2. doi:10.1017/gheg.2016.21
   PubMedGoogle Scholar
• Motulsky AG. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc. 1957;165(7):835–837. doi:10.1001/jama.1957.72980250010016
   PubMed Web of Science ®Google Scholar
• Dandara C, Masimirembwa C, Haffani YZ, et al. African Pharmacogenomics Consortium: consolidating pharmacogenomics knowledge, capacity development and translation in Africa: consolidating pharmacogenomics knowledge, capacity development and translation in Africa. AAS Open Res. 2019;2:19. doi:10.12688/aasopenres.12965.1
   PubMedGoogle Scholar
• Dandara C, Matimba A. A Glimpse into Pharmacogenomics in Africa. Cambridge, UK: Cambridge University Press; 2019.
   Google Scholar
• Tata BE, Ambele M, Pepper M. Barriers to implementing clinical pharmacogenetics testing in Sub-Saharan Africa. A critical review. Pharmaceutics. 2020;12(9):809. doi:10.3390/pharmaceutics12090809
   PubMed Web of Science ®Google Scholar
• Ley B, Luter N, Espino FE, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. BioMed Central. 2015. doi:10.1186/s12936-015-0896-8
   Google Scholar
• Staehli Hodel EM, Csajka C, Ariey F, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2013;57(2):950–958. doi:10.1128/AAC.01700-12
   PubMed Web of Science ®Google Scholar
• Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms—potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004;160(9):825–841. doi:10.1093/aje/kwh294
   PubMed Web of Science ®Google Scholar
• Seripa D, Pilotto A, Panza F, Matera MG, Pilotto A. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev. 2010;9(4):457–474. doi:10.1016/j.arr.2010.06.001
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389–430. doi:10.1146/annurev.pharmtox.38.1.389
   PubMed Web of Science ®Google Scholar
• Feltrin C, Farias IV, Sandjo LP, Reginatto FH, Simões C. Effects of standardized medicinal plant extracts on drug metabolism mediated by CYP3A4 and CYP2D6 enzymes. Chem Res Toxicol. 2020;33(9):2408–2419. doi:10.1021/acs.chemrestox.0c00182
   PubMed Web of Science ®Google Scholar
• Alessandrini M, Asfaha S, Dodgen TM, Warnich L, Pepper MS. Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev. 2013;45(2):253–275. doi:10.3109/03602532.2013.783062
   PubMed Web of Science ®Google Scholar
• El-Shair S, Al Shhab M, Zayed K, Alsmady M, Zihlif M. Association between CYP3A4 and CYP3A5 genotypes and cyclosporine’s blood levels and doses among Jordanian kidney transplanted patients. Curr Drug Metab. 2019;20(8):682–694. doi:10.2174/1389200220666190806141825
   PubMed Web of Science ®Google Scholar
• Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol. 2011;7(10):1185–1200. doi:10.1517/17425255.2011.608660
   PubMed Web of Science ®Google Scholar
• Eng H-S, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 2006;69(10):1858–1864. doi:10.1038/sj.ki.5000325
   PubMed Web of Science ®Google Scholar
• Tang H-L, Ma -L-L, Xie H-G, Zhang T, Hu Y-F. Effects of the CYP3A5* 3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet Genomics. 2010;20(9):525–531. doi:10.1097/FPC.0b013e32833ccd56
   PubMed Web of Science ®Google Scholar
• Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006;45(1):13–31. doi:10.2165/00003088-200645010-00002
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8(4):94. doi:10.3390/biomedicines8040094
   PubMed Web of Science ®Google Scholar
• Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10(9):1489–1510. doi:10.2217/pgs.09.82
   PubMed Web of Science ®Google Scholar
• Cavaco I, Piedade R, Msellem MI, Bjorkman A, Gil JP. Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands. Trop Med Int Health. 2012;17(7):854–857.
   PubMed Web of Science ®Google Scholar
• Johansson T, Jurva U, Gronberg G, Weidolf L, Masimirembwa C. Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR. Drug Metab Dispos. 2009;37(3):571–579. doi:10.1124/dmd.108.025171
   PubMed Web of Science ®Google Scholar
• Phompradit P, Muhamad P, Cheoymang A, Na-Bangchang K. Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria. Am J Trop Med Hyg. 2014;91(2):361. doi:10.4269/ajtmh.13-0531
   PubMed Web of Science ®Google Scholar
• Yusof W, Hua GS. Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods. 2012;22(3):184–192. doi:10.3109/15376516.2011.623331
   PubMed Web of Science ®Google Scholar
• Kerb R, Fux R, Mörike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009;9(12):760–774. doi:10.1016/S1473-3099(09)70320-2
   PubMed Web of Science ®Google Scholar
• Parikh S, Ouedraogo JB, Goldstein J, Rosenthal P, Kroetz D. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82(2):197–203. doi:10.1038/sj.clpt.6100122
   PubMed Web of Science ®Google Scholar
• Tornio A, Backman JT. Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol. 2018;83:3–32.
   PubMedGoogle Scholar
• Hoffman SMG, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenet Genomics. 2001;11(8):687–698. doi:10.1097/00008571-200111000-00007
   Google Scholar
• Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann M, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8(7):743–759. doi:10.2217/14622416.8.7.743
   PubMed Web of Science ®Google Scholar
• Liu H, Xie Y, Cai T, Xing J. No effect of PXR (8055C> T) polymorphism on the pharmacokinetic profiles of piperaquine in healthy Chinese subjects. Curr Drug Metab. 2021;23(2):164–170.
   Web of Science ®Google Scholar
• Gim J-A, Kwon Y, Lee HA, et al. A machine learning-based identification of genes affecting the pharmacokinetics of tacrolimus using the DMETTM plus platform. Int J Mol Sci. 2020;21(7):2517. doi:10.3390/ijms21072517
   PubMed Web of Science ®Google Scholar
• Cavaco IdCL. Molecular determinants of the response to malaria therapeutics; 2007.
   Google Scholar
• Gil JP. The pharmacogenetics of the antimalarial amodiaquine: citeseer; 2012.
   Google Scholar
• Jin J, Lin F, Liao S, Bao Q, Ni L, Wei Q-Y. Effects of SNPs (CYP1B1* 2 G355T, CYP1B1* 3 C4326G, and CYP2E1* 5 G-1293C), smoking, and drinking on susceptibility to laryngeal cancer among Han Chinese. PLoS One. 2014;9(10):e106580. doi:10.1371/journal.pone.0106580
   PubMed Web of Science ®Google Scholar
• Mwenifumbo JC, Lessov‐Schlaggar CN, Zhou Q, et al. Identification of novel CYP2A6* 1B variants: the CYP2A6* 1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther. 2008;83(1):115–121. doi:10.1038/sj.clpt.6100246
   PubMed Web of Science ®Google Scholar
• Ezzeldin N, El-Lebedy D, Darwish A, et al. Association of genetic polymorphisms CYP2A6* 2 rs1801272 and CYP2A6* 9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population. BMC Cancer. 2018;18(1):1–9. doi:10.1186/s12885-018-4342-5
   PubMedGoogle Scholar
• Marwa KJ, Schmidt T, Sjögren M, Minzi OM, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J. 2014;13(1):1–7. doi:10.1186/1475-2875-13-420
   PubMedGoogle Scholar
• Ferreira PE, Veiga MI, Cavaco I, et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit. 2008;30(1):10–15. doi:10.1097/FTD.0b013e31815e93c6
   PubMed Web of Science ®Google Scholar
• Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull World Health Organ. 2011;89:838–845. doi:10.2471/BLT.11.087320
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Health NIo. National Heart Lung, and Blood Institute. Study Quality Assessment Tools. Bethesda, MD, USA: National Institutes of Health; 2018.
   Google Scholar
• Pernaute-Lau L, Morris U, Msellem M, Mårtensson A, Björkman A, Gil JP. Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar. Malar J. 2021;20(1):1–7. doi:10.1186/s12936-021-03620-6
   PubMed Web of Science ®Google Scholar
• Hodoameda P. Determination of Plasmodium Falciparum and Host Genetic Factors That Affect the Efficacy of the Artemisinin-Based Combination Partner Drugs Used in Ghana. University Of Ghana; 2019.
   Google Scholar
• Hodoameda P, Duah-Quashie NO, Hagan CO, et al. Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana. Malar J. 2020;19(1):1–8. doi:10.1186/s12936-020-03320-7
   PubMedGoogle Scholar
• Kiaco K, Rodrigues AS, Do Rosário V, Gil JP, Lopes D. The drug transporter ABCB1 c. 3435C> T SNP influences artemether–lumefantrine treatment outcome. Malar J. 2017;16(1):1–6. doi:10.1186/s12936-017-2006-6
   PubMedGoogle Scholar
• Mutagonda RF, Kamuhabwa AA, Minzi O, et al. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017;16(1):1–10. doi:10.1186/s12936-017-1914-9
   PubMedGoogle Scholar
• Adjei GO, Kristensen K, Goka BQ, et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52(12):4400–4406. doi:10.1128/AAC.00673-07
   PubMed Web of Science ®Google Scholar
• Somé FA, Bazié T, Ehrlich HY, et al. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malar J. 2020;19(1):1–8. doi:10.1186/s12936-020-03311-8
   PubMed Web of Science ®Google Scholar
• Mballa R, Chedjou J, Ngwafor R. Single nucleotide polymorphisms in the cyp2C8 and nat2 genes and treatment outcomes in patients suffering from uncomplicated malaria in Garoua, Northern Region of Cameroon. Pharm Pharmacol Int J. 2019;7(4):147–153.
   Google Scholar
• Habtemikael L, Russom M, Bahta I, et al. Prevalence of CYP2C8* 2 and* 3 among Eritreans and its potential impact on artesunate/amodiaquine treatment. Pharmgenomics Pers Med. 2020;13:571. doi:10.2147/PGPM.S276215
   PubMed Web of Science ®Google Scholar
• Maganda B, Minzi O, Ngaimisi E, Kamuhabwa A, Aklillu E. CYP2B6* 6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16(1):88–95. doi:10.1038/tpj.2015.37
   PubMed Web of Science ®Google Scholar
• Janha RE, Sisay-Joof F, Hamid-Adiamoh M, et al. Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics. 2009;10(9):1423–1431. doi:10.2217/pgs.09.72
   PubMed Web of Science ®Google Scholar
• Kilonzi M, Minzi O, Mutagonda R, et al. Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania. Malar J. 2020;19(1):1–8. doi:10.1186/s12936-020-3150-y
   PubMed Web of Science ®Google Scholar
• Bell DJ, Wootton D, Mukaka M, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8(1):1–11. doi:10.1186/1475-2875-8-204
   PubMedGoogle Scholar
• Marwa KJ, Liwa AC, Konje ET, Mwita S, Kamugisha E, Swedberg G. Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania. Int J Infect Dis. 2022;123:192–199. doi:10.1016/j.ijid.2022.08.020
   PubMed Web of Science ®Google Scholar
• Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5(1):1–8. doi:10.1186/1475-2875-5-59
   PubMedGoogle Scholar
• Ippolito MM, Pringle JC, Siame M, et al. Therapeutic Efficacy of artemether–lumefantrine for uncomplicated falciparum malaria in Northern Zambia. Am J Trop Med Hyg. 2020;103(6):2224. doi:10.4269/ajtmh.20-0852
   PubMed Web of Science ®Google Scholar